Global High-Priority Regulatory Events — February 25, 2026

26-02-2026

26-02-2026

26-02-2026

26-02-2026

26-02-2026

26-02-2026

26-02-2026

26-02-2026

26-02-2026

Arrow Financial Corp filed a Form 8-K on February 26, 2026 (AccNo: 0000717538-26-000030, Size: 48 MB), reporting under Item 1.01 entry into a material definitive agreement, Item 7.01 Regulation FD disclosure, Item 8.01 other events, and Item 9.01 financial statements and exhibits. No quantitative metrics, transaction details, financial impacts, or period-over-period comparisons are disclosed. The large filing size suggests substantial exhibits, likely including the agreement text.

26-02-2026

26-02-2026

Soleno Therapeutics Inc filed an 8-K on 2026-02-26 disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers). The filing also includes Item 8.01 (Other Events) and Item 9.01 (Financial Statements and Exhibits). Specific details on the affected position, person involved, appointment or resignation status, reasons, and any quantitative metrics are NOT_DISCLOSED.

26-02-2026

Cactus, Inc. filed an 8-K on 2026-02-26 disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers), alongside results of operations and financial condition under Item 2.02, and financial statements and exhibits under Item 9.01. Specific details on the affected officer position, name, appointment or resignation, reasons, or timing are NOT_DISCLOSED. No quantitative financial metrics, performance comparisons, or other numerical data are provided in the available information.

26-02-2026

Zura Bio Ltd filed a Form 8-K on 2026-02-26 disclosing entry into a Material Definitive Agreement under Item 1.01, Results of Operations and Financial Condition under Item 2.02, Other Events under Item 8.01, and Financial Statements and Exhibits under Item 9.01 (AccNo: 0001104659-26-019827, size 744 KB). This is a multi-item filing covering a material transaction alongside financial updates, but specific details including transaction value, financial metrics, and performance changes are NOT_DISCLOSED. No quantitative impacts or period-over-period comparisons are available.

• ·Multi-item 8-K filing
• ·Sector: NOT_DISCLOSED

26-02-2026

Warner Bros. Discovery, Inc. filed an 8-K on February 26, 2026, under Items 2.02 (Results of Operations and Financial Condition), 7.01 (Regulation FD Disclosure), and 9.01 (Financial Statements and Exhibits). This is a multi-item filing likely related to an earnings release or financial update. No specific financial metrics, guidance, transaction details, or quantitative data are disclosed in the provided filing summary.

26-02-2026

Vital Farms, Inc. filed an 8-K on 2026-02-26 disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers), alongside results of operations and financial condition (Item 2.02), Regulation FD disclosure (Item 7.01), other events (Item 8.01), and financial statements and exhibits (Item 9.01). Specific details including the key position affected, appointment or resignation status, reason for change, and any financial metrics are NOT_DISCLOSED. No quantitative data, named executives, or scheduled events are provided in the available information.

26-02-2026

Avanos Medical, Inc. filed an 8-K on February 26, 2026, reporting under Item 1.01 entry into a material definitive agreement, under Item 8.01 other events, and under Item 9.01 financial statements and exhibits. No specific details, transaction values, financial metrics, positive or negative impacts, or comparisons were disclosed in the provided filing summary. This is a multi-item mandatory disclosure with no quantitative data available.

26-02-2026

Anika Therapeutics, Inc. filed an 8-K on February 26, 2026, disclosing results of operations and financial condition under Item 2.02 and an officer or director change under Item 5.02, with exhibits under Item 9.01. Specific details on the leadership change, including position affected, appointment or resignation status, reasons, and timing, are NOT_DISCLOSED. No quantitative financial metrics, period-over-period comparisons, or named individuals are provided in the available information.

26-02-2026

E.W. SCRIPPS Co filed an 8-K on February 26, 2026 (AccNo: 0000832428-26-000006), disclosing results of operations and financial condition (Item 2.02), departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements (Item 5.02), other events (Item 8.01), and financial statements and exhibits (Item 9.01). Specific details on the officer change including key position affected, appointment or resignation status, reason, or timing are NOT_DISCLOSED. No quantitative financial metrics, period-over-period comparisons, or other numerical data are disclosed.

26-02-2026

Cognizant Technology Solutions Corp filed an 8-K on 2026-02-26 under Item 5.02 disclosing departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements of certain officers. No specific details on affected positions, individuals, reasons for change, timing, or impacts are provided in the available information. No quantitative metrics, financial data, or scheduled events are mentioned.

26-02-2026

ACI Worldwide, Inc. filed an 8-K on February 26, 2026, disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers), alongside results of operations and financial condition (Item 2.02), Regulation FD disclosure (Item 7.01), and financial statements/exhibits (Item 9.01). No specific details on the officer involved, nature of the change, financial metrics, or any quantitative data are disclosed in the provided filing information. No positive, negative, or flat performance metrics are mentioned.

26-02-2026

Roadzen Inc. filed an 8-K on 2026-02-26 reporting under Item 1.01 entry into a material definitive agreement and under Item 9.01 financial statements and exhibits. No details on the agreement, transaction terms, parties, financial impacts, or metrics are disclosed. This is a multi-item mandatory disclosure with no quantitative data provided.

• ·Filing Accession Number: 0001493152-26-008128
• ·Filing Size: 319 KB

26-02-2026

MVB Financial Corp filed an 8-K on 2026-02-26 reporting entry into a material definitive agreement under Item 1.01 and creation of a direct financial obligation or off-balance sheet arrangement under Item 2.03, with financial statements and exhibits under Item 9.01. No specific details on the agreement, obligation size, terms, or financial impacts are disclosed in the provided information. This represents a multi-item mandatory disclosure with potential balance sheet implications, but lacks quantification.

26-02-2026

26-02-2026

Kymera Therapeutics, Inc. filed a Form 8-K on February 26, 2026, disclosing entry into a new material definitive agreement under Item 1.01, which could signal strategic advancements, but simultaneously reported termination of a prior material definitive agreement under Item 1.02, potentially indicating shifts or disruptions in existing commitments. The filing also covers other events (Item 8.01) and includes financial statements and exhibits (Item 9.01). No specific transaction values, financial impacts, or quantitative metrics are disclosed.

26-02-2026

U S PHYSICAL THERAPY INC /NV filed an 8-K on February 26, 2026, disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers). The filing also includes Regulation FD Disclosure (Item 7.01), Other Events (Item 8.01), and Financial Statements and Exhibits (Item 9.01). Specific details on the officer, position, reason for change, or any impacts are NOT_DISCLOSED.

• ·Filing Accession Number: 0001140361-26-006882
• ·File size: 1 MB
• ·Sector: NOT_DISCLOSED

26-02-2026

Kindly MD, Inc. filed an 8-K on February 26, 2026, disclosing entry into a material definitive agreement (Item 1.01) and completion of an acquisition or disposition of assets (Item 2.01). The filing also covers unregistered sales of equity securities (Item 3.02), departure or election of directors/officers and compensatory arrangements (Item 5.02), Regulation FD disclosure (Item 7.01), and financial statements/exhibits (Item 9.01). No specific transaction details, financial metrics, parties, or values are disclosed.

26-02-2026

Manhattan Associates Inc filed an 8-K on February 26, 2026, disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers), along with Regulation FD Disclosure under Item 7.01 and Financial Statements and Exhibits under Item 9.01. Specific details including the key position affected, whether it is an appointment or resignation, reasons for the change, and timing are NOT_DISCLOSED. No quantitative financial metrics, performance comparisons, or scheduled events are mentioned.

26-02-2026

Redwire Corp filed a multi-item 8-K on February 26, 2026, reporting entry into a new material definitive agreement (Item 1.01), termination of a prior material definitive agreement (Item 1.02), results of operations and financial condition (Item 2.02), and creation of a new direct financial obligation or off-balance sheet arrangement (Item 2.03), with financial statements and exhibits under Item 9.01. No specific details on the agreements, transaction values, financial metrics, or impacts are disclosed. This combination suggests both new commitments and terminations, but lacks quantification for balanced assessment.

26-02-2026

Nuwellis, Inc. filed an 8-K on 2026-02-26 disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers), along with Regulation FD Disclosure under Item 7.01, Other Events under Item 8.01, and Financial Statements and Exhibits under Item 9.01. Specific details on the key position affected, whether it is an appointment or resignation, reasons for the change, and any named individuals are NOT_DISCLOSED. No quantitative metrics, financial data, or scheduled events are mentioned in the provided filing information.

26-02-2026

Kilroy Realty Corp filed an 8-K on February 26, 2026 (AccNo: 0001628280-26-012017), disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers), along with Regulation FD Disclosure under Item 7.01 and Financial Statements and Exhibits under Item 9.01. Specific details including the key position affected, whether it is an appointment or resignation, reasons for the change, and any governance implications are NOT_DISCLOSED. No quantitative data, financial metrics, scheduled events, or further context on board outcomes or succession planning is provided in the available information.

26-02-2026

26-02-2026

26-02-2026

26-02-2026

Soren Acquisition Corp. filed an 8-K on February 26, 2026, under Item 8.01 (Other Events) and Item 9.01 (Financial Statements and Exhibits) disclosing a Merger/Acquisition event. No specific details on deal structure, parties, valuation, financial terms, synergies, or impacts are provided in the filing summary. No quantitative metrics, comparisons, positive or negative changes, or scheduled events mentioned.

26-02-2026

Zoomcar Holdings, Inc. filed a multi-item Form 8-K on 2026-02-26 disclosing entry into a material definitive agreement (Item 1.01) and unregistered sales of equity securities (Item 3.02), accompanied by Regulation FD disclosure (Item 7.01). While Item 1.01 signals a potentially strategic transaction, Item 3.02 raises dilution concerns from equity issuances. No transaction values, financial impacts, or specific details are disclosed.

26-02-2026

26-02-2026

Helios Technologies, Inc. filed an 8-K on 2026-02-26 disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers) and Item 9.01 (Financial Statements and Exhibits). No specific details on the affected officer, position, reason for change, or any quantitative metrics are provided in the filing summary. This appears to be a routine disclosure without additional context on governance or market implications.

26-02-2026

TIGO ENERGY, INC. filed an 8-K on 2026-02-26 reporting under Item 1.01 Entry into a Material Definitive Agreement, Item 8.01 Other Events, and Item 9.01 Financial Statements and Exhibits. Specific details of the material definitive agreement, other events, transaction size, financial impacts, or any quantitative metrics are NOT_DISCLOSED in the provided filing summary. No positive or negative performance metrics, comparisons, or guidance changes are mentioned.

26-02-2026

Elevance Health, Inc. filed an 8-K on 2026-02-26 disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers) and Item 7.01 (Regulation FD Disclosure). No specific details on the affected officer, position, reason for change, or compensatory arrangements are provided in the filing summary. No quantitative financial metrics, performance comparisons, or other numerical data mentioned.

26-02-2026

CHASE PACKAGING CORP filed an 8-K on 2026-02-26 disclosing Item 3.03 Material Modifications to Rights of Security Holders and Item 9.01 Financial Statements and Exhibits. This is a multi-item filing with no quantitative financial metrics, transaction values, period-over-period comparisons, or specific details on the modifications provided in the available information. No positive or negative performance metrics are mentioned.

26-02-2026

UNION BANKSHARES INC filed an 8-K on 2026-02-26 under Item 5.02 disclosing departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements of certain officers. No specific details on affected positions, individuals, reasons for change, timing, or any quantitative data are disclosed in the provided filing information.

26-02-2026

Bicara Therapeutics Inc. filed a Form 8-K on 2026-02-26 reporting entry into a material definitive agreement under Item 1.01 and results of operations and financial condition under Item 2.02, accompanied by financial statements and exhibits under Item 9.01. This is a multi-item mandatory disclosure with no specific transaction details, dollar values, financial metrics, or performance comparisons provided in the available information. No positive or negative metrics are disclosed.

26-02-2026

Insight Molecular Diagnostics Inc. filed a Form 8-K on February 26, 2026 (AccNo: 0001493152-26-008169), disclosing entry into a material definitive agreement under Item 1.01 and providing financial statements and exhibits under Item 9.01. No details on the agreement's parties, terms, value, strategic importance, or financial impacts are disclosed. This is a multi-item mandatory filing with no quantitative metrics or period-over-period comparisons provided.

• ·Filing size: 202 KB
• ·Accession Number: 0001493152-26-008169
• ·Sector: NOT_DISCLOSED

26-02-2026

Teledyne Technologies Inc filed an 8-K on 2026-02-26 under Items 1.01 and 9.01, disclosing entry into a material definitive agreement with financial statements and exhibits attached. No details on the agreement's nature, parties, value, strategic rationale, or financial impacts are provided in the filing summary. No quantitative metrics, period-over-period changes, or scheduled events are mentioned.

26-02-2026

Parsons Corp filed an 8-K on February 26, 2026 (AccNo: 0001193125-26-076537), disclosing an officer change under Item 5.02 related to Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. No specific details on the key position affected, whether it is an appointment or resignation, reasons for the change, or any quantitative impacts are provided. Sector information is not specified.

26-02-2026

MP Materials Corp. filed an 8-K on February 26, 2026, under Item 2.02 disclosing results of operations and financial condition, accompanied by Item 9.01 for financial statements and exhibits. No specific revenue, earnings, guidance, or other quantitative metrics are disclosed in the provided filing summary. This appears to be a standard earnings-related disclosure without detailed financial data available.

26-02-2026

PLUG POWER INC filed an 8-K on 2026-02-26 reporting under Item 1.01 entry into a material definitive agreement, Item 8.01 other events, and Item 9.01 financial statements and exhibits. No specific details on the agreement, transaction size, financial impacts, or other metrics are disclosed in the provided filing summary. No positive or negative metrics, period-over-period comparisons, or guidance changes are mentioned.

26-02-2026

Keros Therapeutics, Inc. filed an 8-K on February 26, 2026, disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers), along with Regulation FD Disclosure under Item 7.01 and Financial Statements and Exhibits under Item 9.01. Specific details including the key position affected, individual names, appointment or resignation status, reasons for change, and timing are NOT_DISCLOSED. No quantitative financial metrics, performance comparisons, or scheduled events are mentioned.

• ·Filing accession number: 0001664710-26-000008
• ·File size: 232 KB
• ·Sector: NOT_DISCLOSED

26-02-2026

Brink's Co filed a Form 8-K on February 26, 2026, reporting under Item 1.01 entry into a material definitive agreement, under Item 7.01 a Regulation FD disclosure, and under Item 9.01 financial statements and exhibits. This is a multi-item filing with no specific details on the agreement's nature, parties, terms, or financial impacts disclosed in the provided information. No quantitative metrics, period-over-period comparisons, or directional performance indicators (positive, negative, or flat) are mentioned.

26-02-2026

Seer, Inc. filed a multi-item Form 8-K on February 26, 2026, reporting entry into a material definitive agreement under Item 1.01, material modifications to rights of security holders under Item 3.03, amendments to articles of incorporation or bylaws under Item 5.03, and Regulation FD disclosure under Item 7.01, with exhibits under Item 9.01. No specific details on the agreement, modifications, amendments, financial impacts, or quantitative metrics are disclosed in the provided filing summary.

26-02-2026

TPG Inc. filed a Form 8-K on February 26, 2026, reporting under Item 1.01 (Entry into a Material Definitive Agreement), Item 2.03 (Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement), Item 8.01 (Other Events), and Item 9.01 (Financial Statements and Exhibits). This is a multi-item mandatory filing triggered by significant corporate developments, but no specific transaction details, dollar values, financial metrics, or quantitative impacts are disclosed. No positive or negative performance metrics, period-over-period changes, or guidance revisions are mentioned.

26-02-2026

Phillips Edison & Company, Inc. filed an 8-K on 2026-02-26 disclosing entry into a material definitive agreement under Item 1.01 and creation of a direct financial obligation or off-balance sheet arrangement under Item 2.03, which are mandatory disclosures. Item 8.01 covers other events and Item 9.01 includes financial statements and exhibits. No specific transaction details, dollar values, financial impacts, or performance metrics (positive, negative, or flat) are disclosed.

• ·Multi-item 8-K filing (Items 1.01, 2.03, 8.01, 9.01)
• ·Filed same day as event date (2026-02-26), indicating timely disclosure

26-02-2026

PureCycle Technologies, Inc. filed a multi-item Form 8-K on February 26, 2026, reporting entry into a material definitive agreement (Item 1.01), results of operations and financial condition (Item 2.02), material modifications to rights of security holders (Item 3.03), departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements (Item 5.02), Regulation FD disclosure (Item 7.01), other events (Item 8.01), and financial statements and exhibits (Item 9.01). No specific transaction details, financial metrics, or quantitative impacts are disclosed in the provided filing summary. This appears to be a comprehensive disclosure covering operational, governance, and strategic updates.

26-02-2026

Sidus Space Inc. filed a Form 8-K on 2026-02-26 reporting under Item 1.01 entry into a Material Definitive Agreement. Item 9.01 discloses Financial Statements and Exhibits. No details on the agreement's nature, parties, dollar value, strategic importance, or financial impacts are provided.

26-02-2026

Advanced Biomed Inc. filed an 8-K on February 26, 2026, disclosing under Item 3.03 material modifications to rights of security holders, under Item 5.03 amendments to articles of incorporation or bylaws or change in fiscal year, under Item 8.01 other events, and Item 9.01 financial statements and exhibits. No specific details, financial impacts, or quantitative metrics regarding these changes or events are provided. This is a multi-item filing with no disclosed positive or negative performance metrics.

26-02-2026

Dexcom Inc filed an 8-K on February 26, 2026 (AccNo: 0001093557-26-000031), disclosing under Item 5.02 a departure of directors or certain officers, election or appointment of directors or officers, and/or compensatory arrangements of certain officers. The filing also includes Regulation FD disclosure under Item 7.01 and financial statements and exhibits under Item 9.01. No specific details on positions affected, individuals involved, reasons for changes, timing, or quantitative impacts are disclosed.

26-02-2026

ITRON, INC. filed a Form 8-K on 2026-02-26 reporting under Item 1.01 entry into a material definitive agreement, Item 2.03 creation of a direct financial obligation or off-balance sheet arrangement, Item 3.02 unregistered sales of equity securities, Item 8.01 other events, and Item 9.01 financial statements and exhibits. This is a multi-item mandatory disclosure with no specific dollar values, share counts, terms, or financial metrics disclosed. Potential implications include strategic shifts, balance sheet changes, and equity dilution, but details are NOT_DISCLOSED.

26-02-2026

AFFILIATED MANAGERS GROUP, INC. filed an 8-K on 2026-02-26 disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers). The filing also includes Regulation FD Disclosure under Item 7.01 and Financial Statements and Exhibits under Item 9.01. No specific details on the officer, position affected, reasons, or any quantitative metrics are disclosed.

26-02-2026

Mayville Engineering Company, Inc. filed a Form 8-K on February 26, 2026, reporting under Item 1.01 entry into a material definitive agreement and under Item 2.03 creation of a direct financial obligation or off-balance sheet arrangement. Item 9.01 includes financial statements and exhibits. No specific transaction details, dollar values, financial impacts, or performance metrics are disclosed.

26-02-2026

NCR Atleos Corp filed an 8-K on 2026-02-26 reporting Item 1.01 Entry into a Material Definitive Agreement, Item 7.01 Regulation FD Disclosure, and Item 9.01 Financial Statements and Exhibits. This is a multi-item filing with a core event of entering a material agreement, accompanied by voluntary disclosure under Reg FD and attached exhibits. No quantitative metrics, financial impacts, transaction values, or specific details on the agreement are disclosed in the provided filing summary.

26-02-2026

Averin Capital Acquisition Corp. filed an 8-K on 2026-02-26 under Item 8.01 (Other Events) announcing a merger/acquisition event and Item 9.01 (Financial Statements and Exhibits). No specific deal structure, parties involved, valuation, financial terms, strategic rationale, or quantitative metrics are disclosed in the filing summary. All key transaction details remain NOT_DISCLOSED.

26-02-2026

Rexford Industrial Realty, Inc. filed an 8-K on 2026-02-26 disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers), along with Regulation FD Disclosure under Item 7.01 and Financial Statements and Exhibits under Item 9.01. Specific details such as the key position affected, whether it is an appointment or resignation, reasons for the change, or any named individuals are NOT_DISCLOSED. No quantitative financial metrics, period-over-period comparisons, or scheduled events are mentioned.

26-02-2026

Ambarella Inc filed an 8-K on 2026-02-26 disclosing Results of Operations and Financial Condition under Item 2.02 and an officer change or election/appointment under Item 5.02, with exhibits under Item 9.01. Specific details on the affected officer position, whether it is an appointment or departure, reasons, or timing are NOT_DISCLOSED. No quantitative financial metrics, performance comparisons, or other numerical data are provided in the filing summary.

26-02-2026

MARA Holdings, Inc. filed a Form 8-K on 2026-02-26 reporting Item 1.01 Entry into a Material Definitive Agreement, Item 7.01 Regulation FD Disclosure, and Item 9.01 Financial Statements and Exhibits. This is a multi-item filing with no specific details on the agreement, transaction terms, financial impacts, or metrics disclosed. All quantitative data, including dollar values and percentages, are NOT_DISCLOSED.

26-02-2026

Arcosa, Inc. filed an 8-K on February 26, 2026, reporting an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers), alongside results of operations and financial condition under Item 2.02, and financial statements/exhibits under Item 9.01. No specific details on the key position affected, individual involved, reason for change, appointment/resignation status, or financial metrics are explicitly stated or quantified in the provided filing information. Sector details are not specified.

26-02-2026

Grindr Inc. filed a Form 8-K on 2026-02-26 reporting entry into a material definitive agreement under Item 1.01 and results of operations and financial condition under Item 2.02, with financial statements and exhibits attached under Item 9.01. This is a multi-item filing with no specific details on the agreement, transaction size, financial metrics, or performance provided in the available information. No positive or negative metrics are disclosed.

26-02-2026

J M Smucker Co filed an 8-K on 2026-02-26 disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers). The filing also includes Item 7.01 (Regulation FD Disclosure). Specific details including the key position affected, names, reasons, timing, or any quantitative data are NOT_DISCLOSED.

26-02-2026

Abbott Laboratories filed an 8-K on 2026-02-26 reporting Item 1.01 Entry into a Material Definitive Agreement and Item 9.01 Financial Statements and Exhibits. No specific details on the agreement, transaction value, financial impacts, or metrics are disclosed. This is a mandatory disclosure of a material event without quantified positive or negative elements.

26-02-2026

PPL Corp filed an 8-K on 2026-02-26 reporting entry into a Material Definitive Agreement under Item 1.01, accompanied by Financial Statements and Exhibits under Item 9.01. No details on the agreement parties, terms, value, strategic rationale, financial impacts, or other metrics are disclosed.

26-02-2026

Federal Signal Corp (/DE/) disclosed an officer change event via 8-K filing on 2026-02-26 under Item 5.02, covering departures of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements of certain officers. Item 9.01 references financial statements and exhibits. No specific details on affected positions, individuals, reasons for change, timing, or any quantitative impacts are provided.

26-02-2026

CBRE Group, Inc. filed an 8-K on February 26, 2026, under Item 5.02 disclosing a departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements of certain officers. Item 9.01 includes financial statements and exhibits. No specific details on individuals, positions, reasons, or impacts are disclosed.

26-02-2026

Texas Ventures Acquisition III Corp filed an 8-K on 2026-02-26 under Item 5.02 regarding departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements of certain officers. No merger/acquisition details, financial metrics, quantitative data, or sector information are disclosed in the filing summary. No positive or negative performance metrics are mentioned.

26-02-2026

Markel Group Inc. filed an 8-K on 2026-02-26 disclosing events under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers) and Item 5.03 (Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year), with exhibits under Item 9.01. Specific details on affected positions, individuals involved, reasons for changes, timing, or impacts are NOT_DISCLOSED. No financial metrics, quantitative data, or scheduled events are mentioned.

26-02-2026

International Media Acquisition Corp. filed an 8-K on 2026-02-26 under Items 8.01 (Other Events) and 9.01 (Financial Statements and Exhibits), disclosing a merger/acquisition-related event. No specific transaction details, parties, values, or metrics were provided in the filing summary. Sector not specified.

26-02-2026

Proficient Auto Logistics, Inc. filed an 8-K on 2026-02-26 disclosing an officer change or related event under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers), alongside Regulation FD Disclosure in Item 7.01 and Financial Statements and Exhibits in Item 9.01. No specific details on the key position affected, whether it is an appointment or resignation, reasons for the change, timing, or any quantitative impacts are disclosed. No positive or negative metrics are provided, resulting in purely informational disclosure.

26-02-2026

CyberloQ Technologies, Inc. filed an 8-K on February 26, 2026 (AccNo: 0001493152-26-008185), reporting under Item 1.01 entry into a material definitive agreement. No additional details on the nature of the agreement, transaction value, financial impacts, parties involved, or strategic rationale were explicitly stated. No quantitative metrics, positive or negative changes, or comparisons were disclosed.

26-02-2026

Applied Optoelectronics, Inc. filed an 8-K on 2026-02-26 reporting Item 1.01 Entry into a Material Definitive Agreement and Item 9.01 Financial Statements and Exhibits. No specific details regarding the agreement's parties, terms, transaction value, financial impacts, or strategic context are disclosed in the provided filing summary. Review of the full 495 KB filing (AccNo: 0001104659-26-020600) is required for complete analysis.

26-02-2026

Eagle Bancorp Montana, Inc. filed an 8-K on 2026-02-26 under Item 5.02 disclosing departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements of certain officers. No specific details on affected positions, individuals involved, reasons for changes, or any quantitative data such as compensation amounts are disclosed. Filing size is 154 KB with AccNo 0001437749-26-005899.

• ·AccNo: 0001437749-26-005899
• ·Sector: NOT_DISCLOSED

26-02-2026

ContextLogic Holdings Inc. filed an 8-K on February 26, 2026, disclosing entry into a material definitive agreement (Item 1.01) and completion of an acquisition or disposition of assets (Item 2.01), which may provide strategic benefits. However, the filing also reveals creation of a direct financial obligation (Item 2.03) and unregistered sales of equity securities (Item 3.02), introducing potential leverage and dilution risks, alongside changes in directors or officers (Item 5.02). Specific details on parties, deal size, or terms are NOT_DISCLOSED.

26-02-2026

Skyward Specialty Insurance Group, Inc. filed an 8-K on 2026-02-26 under Item 5.02 disclosing departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements of certain officers. Item 9.01 references financial statements and exhibits. No specific names, positions affected, reasons for change, timing, or quantitative details are disclosed.

26-02-2026

STONERIDGE INC filed a Form 8-K on 2026-02-26 reporting multiple items: Item 1.01 Entry into a Material Definitive Agreement, Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Item 7.01 Regulation FD Disclosure, and Item 9.01 Financial Statements and Exhibits. No specific details on the agreement, personnel changes, disclosures, dollar values, financial impacts, or quantitative metrics are disclosed in the provided filing summary. This is a multi-item filing with no period-over-period comparisons, guidance, or scheduled events mentioned.

26-02-2026

Metropolitan Bank Holding Corp. filed a multi-item Form 8-K on February 26, 2026, reporting under Item 1.01 entry into a material definitive agreement, under Item 7.01 a Regulation FD disclosure, and under Item 9.01 financial statements and exhibits. No specific details on the agreement, transaction terms, financial impacts, or disclosures are provided in the available metadata. This is an informational filing with no quantified metrics or period-over-period comparisons disclosed.

26-02-2026

CenterPoint Energy Inc filed an 8-K on February 26, 2026, disclosing under Item 1.01 entry into a material definitive agreement, under Item 2.03 the creation of a direct financial obligation or off-balance sheet arrangement, and under Item 3.02 unregistered sales of equity securities. Item 9.01 references attached financial statements and exhibits. No specific transaction values, financial impacts, positive or negative metrics, or other quantitative details are disclosed.

26-02-2026

Civista Bancshares, Inc. filed an 8-K on 2026-02-26 disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers). Item 9.01 indicates Financial Statements and Exhibits were included. No specific details on positions affected, names, reasons, timing, or any quantitative metrics are disclosed.

26-02-2026

Legato Merger Corp. III filed an 8-K on 2026-02-26 disclosing entry into a Material Definitive Agreement under Item 1.01, likely related to a merger/acquisition, along with Regulation FD Disclosure under Item 7.01 and Financial Statements and Exhibits under Item 9.01. No specific deal structure, parties, valuation, synergies, or financial metrics are disclosed in the provided filing summary. This informational filing signals a significant transaction but lacks details for full assessment.

• ·Filing Accession Number: 0001829126-26-001675
• ·File Size: 919 KB

26-02-2026

NewMarket Corp filed an 8-K on 2026-02-26 disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers). Item 9.01 indicates Financial Statements and Exhibits were included. No specific details on the affected position, individual names, appointment/resignation status, reasons, or impacts are disclosed.

26-02-2026

KB Home filed an 8-K on 2026-02-26 disclosing officer changes under Item 5.02, which covers departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements of certain officers. The filing also reports other events under Item 8.01 and includes financial statements and exhibits under Item 9.01. No specific details such as names, titles, reasons for changes, timing, financial metrics, or quantitative impacts are disclosed.

26-02-2026

Boston Scientific Corp filed a multi-item 8-K on February 26, 2026, disclosing entry into a material definitive agreement (Item 1.01) while terminating a prior material definitive agreement (Item 1.02). The filing also reports the creation of a direct financial obligation or off-balance sheet arrangement (Item 2.03), with financial statements and exhibits under Item 9.01. No specific transaction values, parties, terms, or financial impacts are disclosed.

26-02-2026

Nixxy, Inc. filed an 8-K on 2026-02-26 under Item 3.01 announcing a notice of delisting or failure to satisfy a continued listing rule or standard, with transfer of listing. No financial metrics, transaction values, or other quantitative data disclosed. Sector not specified.

• ·Accession Number: 0001683168-26-001318
• ·Filing size: 239 KB

26-02-2026

Propanc Biopharma, Inc. filed an 8-K on 2026-02-26 disclosing an officer or director change under Item 5.02, which covers departures of directors or certain officers, elections or appointments of directors or officers, and compensatory arrangements of certain officers. Item 9.01 references financial statements and exhibits. No specific details on positions affected, names, appointment or resignation status, reasons, timing, or compensation are disclosed.

26-02-2026

Technology & Telecommunication Acquisition Corp filed an 8-K on 2026-02-26 disclosing entry into a material definitive agreement under Item 1.01, likely related to a merger or acquisition. The filing also covers amendments to articles of incorporation or bylaws and potential change in fiscal year under Item 5.03, as well as submission of matters to a vote of security holders under Item 5.07, with financial statements and exhibits under Item 9.01. No specific transaction parties, terms, valuations, synergies, or financial metrics are disclosed.

26-02-2026

CNX Resources Corp filed an 8-K on February 26, 2026, reporting under Item 1.01 entry into a material definitive agreement, Item 2.03 creation of a direct financial obligation or off-balance sheet arrangement, Item 7.01 Regulation FD disclosure, and Item 9.01 financial statements and exhibits. No specific transaction details, dollar values, financial metrics, or performance comparisons (positive, negative, or flat) were disclosed in the filing summary. This multi-item filing indicates significant corporate actions but lacks quantitative data for impact assessment.

26-02-2026

NKGen Biotech, Inc. filed a Form 8-K on February 26, 2026, reporting under Item 1.01 entry into a material definitive agreement and under Item 2.03 the creation of a direct financial obligation or an obligation under an off-balance sheet arrangement. Item 9.01 discloses financial statements and exhibits, likely including the agreement. No quantitative details, financial impacts, positive or negative metrics, or further context on the transaction are provided.

26-02-2026

Vir Biotechnology, Inc. filed an 8-K on 2026-02-26 disclosing entry into a material definitive agreement under Item 1.01, with exhibits under Item 9.01 (AccNo: 0001193125-26-077416, file size 442 KB). No specific details on the agreement terms, transaction value, financial impacts, or strategic rationale are provided. No quantitative metrics, positive or negative changes, or performance comparisons are mentioned.

• ·File size: 442 KB
• ·Sector: not specified

26-02-2026

Macerich Co filed an 8-K on 2026-02-26 under Item 1.01 disclosing entry into a material definitive agreement and under Item 2.03 creation of a direct financial obligation or an obligation under an off-balance sheet arrangement of the registrant. Item 9.01 includes financial statements and exhibits. No quantitative details such as transaction values, financial impacts, or comparisons are disclosed.

26-02-2026

Palvella Therapeutics, Inc. filed an 8-K on 2026-02-26 reporting under Item 1.01 entry into a material definitive agreement. Item 9.01 discloses financial statements and exhibits. No transaction details, financial metrics, dollar values, or impacts are disclosed.

• ·Filing Accession Number: 0001104659-26-020667
• ·File Size: 584 KB
• ·Event Date: 2026-02-26
• ·Sector: not specified
• ·Multi-item 8-K filing (Items 1.01 and 9.01)
• ·Mandatory disclosure under Item 1.01 for material agreements

26-02-2026

NuScale Power Corp filed an 8-K on February 26, 2026, reporting entry into a material definitive agreement under Item 1.01 while simultaneously disclosing termination of another material definitive agreement under Item 1.02. Item 9.01 provides financial statements and exhibits. This mixed disclosure signals potential strategic advancement from the new agreement but disruption from the termination, with no specific financial or operational details provided.

26-02-2026

FTAI Infrastructure Inc. filed an 8-K on 2026-02-26 disclosing entry into a material definitive agreement under Item 1.01 and termination of a material definitive agreement under Item 1.02. The filing also includes results of operations and financial condition under Item 2.02, with financial statements and exhibits under Item 9.01. No specific transaction details, financial metrics, or quantitative impacts are disclosed.